Encorafenib plus cetuximab (EC) plus FOLFIRI for BRAF V600E-mutant metastatic colorectal cancer (mCRC): Updated results from the BREAKWATER safety lead-in (SLI)

by biblioteca on 10 de juny de 2025 with No hi ha comentaris

Tabernero, J., Yoshino, T., Kim, T., Yaeger, R., Desai, J., Wasan, H.,…Kopetz, S. (2024). Encorafenib plus cetuximab (EC) plus FOLFIRI for BRAF V600E-mutant metastatic colorectal cancer (mCRC): Updated results from the BREAKWATER safety lead-in (SLI). Annals of Oncology, 35, S435-S436. https://doi.org/10.1016/j.annonc.2024.08.584 (Meeting abstract)